CClinicalTrials.gg
Status unknownNCT02371486Updated Oct 14, 2016

Does Cesarean Section Scar Defect (Niche) Affect Implantation Rate?

An interventional study of hysteroscopic repair of cesarean section defect and Diagnostic Hysteroscopy in Infertility and Complications; Cesarean Section, sponsored by Sheba Medical Center. Status unknown at 1 site in Israel. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2016-10-14.

Sponsored by Sheba Medical Center · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2016), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

Cesarean scar defects (CSDs), i.e. deficient uterine scars following a cesarean section, involve discontinuity at the site of a previous Cesarean section scar. These anatomical defects have been reported to be associated with postmenstrual spotting, chronic pelvic pain and infertility. Few case series have suggested improved fertility (most probably by improving implantation of embryos) The aim of this study is to prospectively record embryonal implantation rate during IVF in patients with CSDs, and to evaluate the effect of hysteroscopic repair of CSDs on fetal implantation during IVF.

Read the detailed description

150 patients undergoing IVF after cesarean section will be recruited. demographic, clinical and treatment data will be collected. ultrasound and hysteroscopic evaluation of the CSD will be performed. IVF treatment will be provided. In case of failure of IVF treatment, patients will be randomized to hysteroscopic repair of CSD versus second IVF treatment

02

Conditions studied

  • Infertility
  • Complications; Cesarean Section

Browse trials for

Keywords

  • cesarean section defect
  • implantation
  • ivf
03

In context

Infertility

2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.

This study's planned enrollment of 150 is above the median of 120 across 1,698 interventional studies indexed under Infertility.

Browse Infertility studies →

Lead sponsor

Sheba Medical Center is the lead sponsor of 660 studies on the registry; 63 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Patients undergoing IVF after cesarean section

Exclusion criteria

Exclusion Criteria:

  • Patients who underwent CSD repair
  • Patients with low ovarian reserve
  • Patients with hydrosalpinges, endometriosis, adenomyosis, submucous fibroids or polyps
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Nich Repair

    Interventions to be administered: 1. Ultrasound Scan 2. Diagnostic Hysteroscopy 3. hysteroscopic repair of cesarean section defect 4. IVF cycle

    Procedure: hysteroscopic repair of cesarean section defect · Procedure: Diagnostic Hysteroscopy · Procedure: Ultrasound Scan · Procedure: IVF Cycle

  • Sham comparator
    No Repair

    Interventions to be administered: 1. Ultrasound Scan 2. Diagnostic Hysteroscopy 3. IVF cycle Operative hysteroscopy WILL NOT BE PERFORMED

    Procedure: Diagnostic Hysteroscopy · Procedure: Ultrasound Scan · Procedure: IVF Cycle

Interventions

  • Procedurehysteroscopic repair of cesarean section defect

    Operative hysteroscopy for the repair of cesarean section defect is performed under general anesthesia. the cervix is dilated and the cesarean section defect opened. polypoid tissue is ablated

    Also known as: hysteroscopic metroplasty, niche repair

  • ProcedureDiagnostic Hysteroscopy

    Betthochi's method for diagnostic hysteroscopy: No anesthesia will be used. vaginoscopy will be performed, followed by diagnostic hysteroscopy. saline will be used as a distension media. 4.2 mm Storz hysteroscope will be used.

  • ProcedureUltrasound Scan

    Scanning the uterus with the ultrasound probe . Transvaginal ultrasound usually produces better and clearer images of the female pelvic organs, because the ultrasound probe lies closer to these structures. The transvaginal ultrasound probe is thin, about 2cm diameter. The probe is covered with a disposable protective sheath. A small amount of ultrasound gel is placed on the end of this probe. The probe is then gently inserted a short distance into the vagina.

    Also known as: Internal ultrasound

  • ProcedureIVF Cycle

    Controlled ovarian hyperstimulation, followed by Human chorionic Gonadotropin ( hCG) administration, Ovum Pickup and Embryo transfer

    Also known as: IVF Treatment

06

What researchers measure

Primary outcomes

  1. Embryo implantation rate

    Embryo implantation rate during IVF

    Time frame: completion of two IVF cycles after randomization - approx. 2 months

Secondary outcomes

  1. Fluid in Uterus

    Detection of fluid in the uterine cavity during menotropin stimulation in IVF treatment

    Time frame: completion of two IVF cycles after randomization - approx. 2 months

  2. Correlation between size and type of the defect fluid accumulation

    Correlation between the size and type of the defect and the detection of fluid in the uterine cavity during menotropin stimulation in IVF treatment

    Time frame: completion of two IVF cycles after randomization - approx. 2 months

  3. Correlation between the size and type of the defect and implantation rate during IVF treatment

    Correlation between the size and type of the defect and implantation rate during IVF treatment

    Time frame: completion of two IVF cycles after randomization - approx. 2 months

07

Study locations

1 of 1 sites recruiting
  • The chaim sheba medical center,Tel Hashomer
    Ramat Gan, 52503, Israel
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02371486
Lead sponsor
Sheba Medical Center
Responsible party
Roy Mashiach, M.D. (Vice Chairman Gynecological Department, Sheba Medical Center) — Principal investigator
First posted
Feb 25, 2015
Start date
Apr 2016
Primary completion
Feb 2017 (estimated)
Completion
Feb 2018 (estimated)
Last update
Oct 14, 2016

Study contacts

Lilia Margolis-Dorfman, M.P.H
Contact
lilia.mdorfman@gmail.com
+972-3530-4948
Roy Mashiach, M.D
Contact
Roy.mashiach@gmail.com
+972-35302773

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion